Kezar CEO Nets About $300k in Cash as Aurinia Merger Clears His Stock Holdings

Context Aurinia Pharma U.S., Inc. completed a tender offer for Kezar Life Sciences’ common stock under a merger agreement. Each tendered share gave the holder $6.955 in cash after taxes plus one contingent value right (CVR), which pays out only if certain future milestones are met. CVRs are not tradable on public markets.

Key Facts Kirk turned in 43,134 shares, generating about $300,000 in cash (43,134 × $6.955 ≈ $299,995). He also received one CVR per share, for a total of 43,134 CVRs. The filing shows dispositions of multiple employee stock options at various exercise prices; out‑of‑the‑money options were cancelled with no payment, while in‑the‑money options were converted to cash based on the spread over the cash amount plus a CVR. After these steps, his reported direct holdings of common stock and options are zero.

What It Means The CEO no longer holds equity or options in Kezar, which may shift his incentives from long‑term stock performance to cash‑based rewards. The CVRs remain a potential future payout if Aurinia hits the agreed milestones, but they carry no immediate value or market liquidity. Investors will watch whether those milestones are met and if Kezar’s board grants new equity or cash compensation to align leadership with shareholder interests.

What to watch next Whether the contingent value rights trigger payments and how Kezar structures future executive compensation now that the CEO’s equity stake is gone.